Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Grünenthal Group
Pharma
Bayer sells cancer drug Stivarga to Grünenthal for up to $431M
Patent protection for Stivarga is expected to last until 2029 in the EU and 2030 in the U.S., but has already expired in China.
Angus Liu
Sep 21, 2026 10:20am
Grünenthal acquires Valinor Pharma and Movantik for $250M
Jul 22, 2024 11:12am
Grünenthal plants in South America will get $87M in upgrades
Jul 17, 2024 2:24pm
Eisai, BeiGene, Shionogi—Fierce Pharma Asia
Dec 2, 2022 10:00am
Kyowa Kirin offloads mature drugs to Grünenthal in Europe
Nov 28, 2022 11:00am
Grünenthal buys up Nebido from Bayer for $500 million
Jul 14, 2022 9:44am
